BioSpace News Archive

eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced the addition of Caroline Loewy to its Board of Directors and her election as Chair of the Board’s Audit Committee.

Positive high-level results from the MANDARA Phase III trial showed AstraZeneca’s FASENRA (benralizumab) met the primary endpoint of the trial and demonstrated non-inferior rates of remission compared to mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) who were receiving oral corticosteroids (OCS) with or without stable immunosuppressive therapy.

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental Biologics License Application (COMIRNATY 2023-2024 Formulation) for individuals 12 years and older and granted emergency use authorization for individuals 6 months through 11 years of age for the companies’ Omicron XBB.1.5-adapted monovalent COVID-19 vaccine.

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) today announced that its Chief Executive Officer Jon Congleton, and Chief Financial Officer and Chief Business Officer, Adam Levy, will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference in New York on Thursday, September 28, 2023 at 9:10 a.m. ET.

Palisade Bio, Inc. is announcing that it has closed its previously announced registered direct offering with institutional investors for the purchase of 2,339,398 shares of common stock for gross proceeds of $1,965,094.32.

Sight Sciences, Inc., an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023.

Crinetics Pharmaceuticals, Inc. announced that it intends to offer and sell, subject to market and other conditions, $250.0 million of shares of its common stock in an underwritten public offering.

First Light Acquisition Group, Inc. announced that it anticipates completing its business combination with Calidi Biotherapeutics on September 12, 2023.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, effective September 25, 2023.

Amphastar Pharmaceuticals, Inc. announced that it intends to offer, subject to market conditions and other factors, $300.0 million aggregate principal amount of convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.